HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abella, A. Articles by Zorzano, A. Search for Related Content PubMed PubMed Citation Articles by Abella, A. Articles by Zorzano, A. Social Bookmarking                What's this?

Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 Activity Exerts an Antidiabetic Action in Goto-Kakizaki Rats

¹ Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, and Parc Científic de Barcelona, Barcelona, Spain
² Endocrinology and Diabetes Unit, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain
³ Institut National de la Santé et de la Recherche Médicale (INSERM U 317), Toulouse, France

In this study we have explored whether the bifunctional protein semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) represents a novel target for type 2 diabetes. To this end, Goto-Kakizaki (GK) diabetic rats were treated with the SSAO substrate benzylamine and with low ineffective doses of vanadate previously shown to have antidiabetic effects in streptozotocin-induced diabetic rats. The administration of benzylamine in combination with vanadate in type 2 diabetic rats acutely stimulated glucose tolerance, and the chronic treatment normalized hyperglycemia, stimulated glucose transport in adipocytes, and reversed muscle insulin resistance. Acute in vivo administration of benzylamine and vanadate stimulated skeletal muscle glucose transport, an effect that was also observed in incubated muscle preparations coincubated with adipose tissue explants or with human recombinant SSAO. Acute administration of benzylamine/vanadate also ameliorated insulin secretion in diabetic GK rats, and this effect was also observed in incubated pancreatic islets. In keeping with these observations, we also demonstrate that pancreatic islets express SSAO/VAP-1. As far as mechanisms of action, we have found that benzylamine/vanadate causes enhanced tyrosine phosphorylation of proteins and reduced protein tyrosine phosphatase activity in adipocytes. In addition, incubation of human recombinant SSAO, benzylamine, and vanadate generates peroxovanadium compounds in vitro. Based on these data, we propose that benzylamine/vanadate administration generates peroxovanadium locally in pancreatic islets, which stimulates insulin secretion and also produces peroxovanadium in adipose tissue, activating glucose metabolism in adipocytes and in neighboring muscle. This opens the possibility of using the SSAO/VAP-1 activity as a local generator of protein tyrosine phosphatase inhibitors in antidiabetic therapy.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Garcia-Vicente, F. Yraola, L. Marti, E. Gonzalez-Munoz, M. J. Garcia-Barrado, C. Canto, A. Abella, S. Bour, R. Artuch, C. Sierra, et al. Oral Insulin-Mimetic Compounds That Act Independently of Insulin Diabetes, February 1, 2007; 56(2): 486 - 493. [Abstract] [Full Text] [PDF]

				M. Salmi and S. Jalkanen Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans Blood, September 1, 2006; 108(5): 1555 - 1561. [Abstract] [Full Text] [PDF]

				M. C. Iglesias-Osma, M. J. Garcia-Barrado, V. Visentin, M. F. Pastor-Mansilla, S. Bour, D. Prevot, P. Valet, J. Moratinos, and C. Carpene Benzylamine Exhibits Insulin-Like Effects on Glucose Disposal, Glucose Transport, and Fat Cell Lipolysis in Rabbits and Diabetic Mice J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1020 - 1028. [Abstract] [Full Text] [PDF]